Fedro A Peccatori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1546397/publications.pdf

Version: 2024-02-01

275 papers

13,119 citations

²⁶⁶³⁰
56
h-index

107

284 all docs

284 docs citations

times ranked

284

11881 citing authors

g-index

#	Article	IF	CITATIONS
1	ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016–2019). Journal of Cancer Education, 2022, 37, 1239-1244.	1.3	7
2	Italian pediatric and adult oncology communities join forces for a national project dedicated to adolescents and young adults with cancer. Tumori, 2022, 108, 104-110.	1.1	8
3	ESO's career development program (2002-2021): Presentation and evaluation. Critical Reviews in Oncology/Hematology, 2022, 169, 103576.	4.4	O
4	Anti-Mýllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Human Reproduction Update, 2022, 28, 417-434.	10.8	40
5	Weekly Paclitaxel Administered During a Twin Pregnancy for Recurrent Breast Cancer: Case Report and Review of the Literature. Journal of Adolescent and Young Adult Oncology, 2022, 11, 632-636.	1.3	1
6	Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. Current Oncology Reports, 2022, 24, 843-860.	4.0	6
7	Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten. Tumori, 2022, 108, 402-406.	1.1	4
8	Changing the landscape of European School of Oncologyâ€"European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic. Future Oncology, 2022, 18, 2857-2864.	2.4	1
9	Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey. Cancers, 2022, 14, 3457.	3.7	6
10	Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. Critical Reviews in Oncology/Hematology, 2021, 157, 103201.	4.4	26
11	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Journal of Cancer Education, 2021, 36, 556-560.	1.3	5
12	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Npj Breast Cancer, 2021, 7, 16.	5.2	13
13	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. European Journal of Cancer, 2021, 144, 310-316.	2.8	34
14	Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review. International Journal of Gynecological Cancer, 2021, 31, 360-370.	2.5	14
15	Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open, 2021, 6, 100096.	4.5	104
16	"Lights and Shadows― An Interpretative Phenomenological Analysis of the Lived Experience of Being Diagnosed With Breast Cancer During Pregnancy. Frontiers in Psychology, 2021, 12, 620353.	2.1	4
17	First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. Journal of Thoracic Oncology, 2021, 16, 873-877.	1.1	18
18	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. JAMA Network Open, 2021, 4, e2113180.	5.9	27

#	Article	IF	CITATIONS
19	The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions. Journal of Cancer Education, 2021, , 1.	1.3	1
20	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	1.6	70
21	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Frontiers in Oncology, 2021, 11, 723693.	2.8	8
22	Educational contribution of the College of the European School of Oncology to the Latin American Oncologists. Future Oncology, 2021, 17, 2981-2987.	2.4	1
23	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	2.8	7
24	Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting. BMC Medicine, 2021, 19, 205.	5.5	30
25	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	2.2	31
26	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	1.0	2
27	Eight-Year Experience of the Certificate of Competence and Advanced Studies Program Organized by the European School of Oncology. Journal of Cancer Education, 2021, , 1.	1.3	1
28	Fertility Counseling in Survivors of Cancer in Childhood and Adolescence: Time for a Reappraisal?. Cancers, 2021, 13, 5626.	3.7	1
29	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open, 2021, 6, 100300.	4.5	9
30	Exploring differences in psychological aspects during pregnancy between cancer survivors and women without a history of cancer. Supportive Care in Cancer, 2020, 28, 2255-2263.	2.2	8
31	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. Critical Reviews in Oncology/Hematology, 2020, 146, 102798.	4.4	9
32	Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. Breast Care, 2020, 15, 148-156.	1.4	32
33	Dealing with death in cancer care: should the oncologist be an amicus mortis?. Supportive Care in Cancer, 2020, 28, 2753-2759.	2.2	4
34	Breastfeeding After Breast Cancer: Feasibility, Safety, and Ethical Perspectives. Journal of Human Lactation, 2020, 36, 40-43.	1.6	3
35	Motherhood during or after breast cancer diagnosis: A qualitative study. European Journal of Cancer Care, 2020, 29, e13214.	1.5	20
36	Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelinesâ€. Annals of Oncology, 2020, 31, 1664-1678.	1.2	243

3

#	Article	IF	Citations
37	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. Journal of Clinical Oncology, 2020, 38, 3012-3023.	1.6	69
38	Management of HER2-positive breast cancer during pregnancy: a case report. Tumori, 2020, 106, NP33-NP35.	1.1	2
39	The impact of the European School of Oncology masterclass in clinical oncology on self-professional development. Critical Reviews in Oncology/Hematology, 2020, 151, 102976.	4.4	5
40	Fertility preservation in women with cervical cancer. Critical Reviews in Oncology/Hematology, 2020, 154, 103092.	4.4	13
41	Pregnancy and Lactation: Risk or Protective Factors for Breast Cancer?. Advances in Experimental Medicine and Biology, 2020, 1252, 195-197.	1.6	10
42	Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. European Journal of Cancer, 2020, 138, 57-67.	2.8	31
43	Pregnancy-associated cancers: frequency and temporal trends in Italy. International Journal of Gynecological Cancer, 2020, 30, 241-244.	2.5	5
44	Seeing beyond COVID-19: understanding the impact of the pandemic on oncology, and the importance of preparedness. History and Philosophy of the Life Sciences, 2020, 42, 57.	1.1	2
45	First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study. ESMO Open, 2020, 5, e000859.	4. 5	6
46	COVID-19: a plea to protect the older population. International Journal for Equity in Health, 2020, 19, 72.	3.5	18
47	Estimation of historical control rate for a single arm de-escalation study $\hat{a} \in \text{Application}$ to the POSITIVE trial. Breast, 2020, 53, 1-7.	2.2	13
48	Fertility preservation strategies in borderline ovarian tumor recurrences: different sides of the same coin. Journal of Assisted Reproduction and Genetics, 2020, 37, 1217-1219.	2.5	8
49	ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. Lancet Oncology, The, 2020, 21, e360-e368.	10.7	50
50	Frequency of Pregnancy-Associated Cancer: A Systematic Review of Population-Based Studies. Cancers, 2020, 12, 1356.	3.7	28
51	The clinical training centers fellowships: a European School of Oncology career development program (2013 $\hat{a} \in \mathbb{C}^n$ 2019). Future Oncology, 2020, 16, 1969-1976.	2.4	5
52	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Journal of Cancer Education, 2020, 36, 1124-1128.	1.3	5
53	Epidemiology and General Considerations of Pregnancy Following Cancer Diagnosis., 2020,, 3-7.		2
54	Fertility Preservation and Pregnancy After Breast Cancer. , 2020, , 167-176.		1

#	Article	IF	CITATIONS
55	Lactation during and after Breast Cancer. Advances in Experimental Medicine and Biology, 2020, 1252, 159-163.	1.6	7
56	Chemotherapy for breast cancer during pregnancy induces vascular alterations and impaired development of placental villi: A preliminary histopathological study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 250, 155-161.	1.1	3
57	Fertility preservation in endocrine responsive breast cancer: data and prejudices. Ecancermedicalscience, 2020, 14, 1157.	1.1	2
58	Cancer During Pregnancy: The Role of Vascular Toxicity in Chemotherapy-Induced Placental Toxicity. Cancers, 2020, 12, 1277.	3.7	10
59	Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians. ESMO Open, 2020, 5, e000956.	4.5	6
60	Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment. Ecancermedicalscience, 2019, 13, 930.	1.1	1
61	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. Cancers, 2019, 11, 1641.	3.7	22
62	Breastfeeding during R-CHOP chemotherapy: please abstain!. European Journal of Cancer, 2019, 119, 107-111.	2.8	10
63	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. Journal of Ovarian Research, 2019, 12, 9.	3.0	83
64	Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. ESMO Open, 2019, 4, e000467.	4.5	14
65	Breast cancer risk of hormonal contraception: Counselling considering new evidence. Critical Reviews in Oncology/Hematology, 2019, 137, 123-130.	4.4	27
66	Effects of in-utero exposure to chemotherapy on fetal brain growth. International Journal of Gynecological Cancer, 2019, 29, 1195-1202.	2.5	8
67	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844.	2.4	29
68	Chemotherapy-related damage to ovarian reserve in childhood cancer survivors: interpreting the evidence. Journal of Assisted Reproduction and Genetics, 2019, 36, 341-348.	2.5	12
69	BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy Journal of Clinical Oncology, 2019, 37, 5572-5572.	1.6	0
70	Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery. Ecancermedicalscience, 2019, 13, 979.	1.1	2
71	EP668â€Cancer in pregnancy: a 15-year descriptive analysis of 86 consecutive patients. , 2019, , .		0
72	Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). Breast, 2018, 39, 131-138.	2,2	167

#	Article	lF	CITATIONS
73	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. European Journal of Cancer, 2018, 92, S22.	2.8	1
74	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncology, The, 2018, 19, 337-346.	10.7	235
75	The ethical plausibility of the â€~Right To Try' laws. Critical Reviews in Oncology/Hematology, 2018, 122, 64-71.	4.4	21
76	Breast Cancer in Special Groups: Breast Cancer in Pregnancy. , 2018, , 511-520.		0
77	Response. Journal of the National Cancer Institute, 2018, 110, 919-920.	6.3	2
78	BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients. Annals of Oncology, 2018, 29, 26-28.	1.2	8
79	Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?. Human Reproduction, 2018, 33, 181-187.	0.9	44
80	Psychological issues and construction of the mother-child relationship in women with cancer during pregnancy: a perspective on current and future directions. BMC Psychology, 2018, 6, 10.	2.1	30
81	Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta Oncol $ ilde{A}^3$ gica, 2018, 57, 1131-1133.	1.8	7
82	A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene. Cancer Prevention Research, 2018, 11, 38-43.	1.5	21
83	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. Journal of the National Cancer Institute, 2018, 110, 426-429.	6.3	143
84	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Research and Treatment, 2018, 168, 551-557.	2.5	33
85	Fertility preservation in ovarian tumours. Ecancermedicalscience, 2018, 12, 885.	1.1	16
86	Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences. Cancer Biology and Medicine, 2018, 15, 6.	3.0	36
87	Supporting Supportive Care in Cancer: The ethical importance of promoting a holistic conception of quality of life. Critical Reviews in Oncology/Hematology, 2018, 131, 90-95.	4.4	18
88	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	2.2	75
89	Tumor progression and metastatic dissemination in ovarian cancer after doseâ€dense or conventional paclitaxel and cisplatin plus bevacizumab. International Journal of Cancer, 2018, 143, 2187-2199.	5.1	8
90	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. Npj Breast Cancer, 2018, 4, 23.	5 . 2	26

#	Article	IF	Citations
91	Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial Journal of Clinical Oncology, 2018, 36, 552-552.	1.6	O
92	Becoming mothers after cancer: Resilience as a protective factor for prenatal attachment and for negative moods during pregnancy Journal of Clinical Oncology, 2018, 36, e22156-e22156.	1.6	1
93	Chemotherapy-induced placental toxicity: The role of vascular toxicity Journal of Clinical Oncology, 2018, 36, e13097-e13097.	1.6	O
94	POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy Journal of Clinical Oncology, 2018, 36, TPS596-TPS596.	1.6	2
95	Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?. European Review for Medical and Pharmacological Sciences, 2018, 22, 246-249.	0.7	3
96	Frequency of Pregnancy Related Cancer. International Journal of Gynecological Cancer, 2017, 27, 613-619.	2.5	7 5
97	3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	1.2	865
98	Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Critical Reviews in Oncology/Hematology, 2017, 113, 90-96.	4.4	42
99	A survey on physicians' knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients. Breast, 2017, 32, S85-S86.	2.2	4
100	3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	2.2	171
101	Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. European Journal of Cancer, 2017, 71, 25-33.	2.8	79
102	The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO Open, 2017, 2, e000252.	4.5	48
103	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast, 2017, 35, 203-217.	2.2	203
104	Fertility and pregnancy issues in BRCA -mutated breast cancer patients. Cancer Treatment Reviews, 2017, 59, 61-70.	7.7	68
105	Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinumâ€free interval: Myth or reality?. Cancer, 2017, 123, 3450-3459.	4.1	48
106	Whole body MRI for systemic staging of breast cancer in pregnant women. Breast, 2017, 35, 177-181.	2.2	40
107	Electron Beam Intraoperative Radiotherapy (ELIOT) in Pregnant Women with Breast Cancer: From in Vivo Dosimetry to Clinical Practice. Breast Care, 2017, 12, 396-400.	1.4	11
108	Reply to M. Lambertini et al. Journal of Clinical Oncology, 2017, 35, 805-806.	1.6	1

#	Article	IF	CITATIONS
109	Long and Winding Road of Cancer and Pregnancy: A Need for Action. Journal of Clinical Oncology, 2017, 35, 1499-1500.	1.6	3
110	Safety of pregnancy in patients (pts) with history of estrogen receptor positive (ER+) breast cancer (BC): Long-term follow-up analysis from a multicenter study Journal of Clinical Oncology, 2017, 35, LBA10066-LBA10066.	1.6	4
111	Fertility Issues in Patients with Breast Cancer or Survivors. , 2017, , 729-737.		o
112	Abstract P1-05-17: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling. , 2017, , .		0
113	Abstract 1452: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling. , 2017, , .		0
114	Risk-reducing Salpingo–Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. Anticancer Research, 2017, 37, 5241-5248.	1.1	11
115	Breast Cancer in Young Women - News from the BCY3 Consensus Conference. Breast Care, 2016, 11, 432-435.	1.4	0
116	Fertility preservation in women with borderline ovarian tumours. Cancer Treatment Reviews, 2016, 49, 13-24.	7.7	36
117	Sclerosing angiomatoid nodular transformation of the spleen during pregnancy: Diagnostic challenges and clinical management. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1021-1025.	1.3	6
118	Managing pregnancy-associated breast cancer: Is more really better?. Breast, 2016, 30, 215-216.	2.2	4
119	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
120	ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016. Annals of Oncology, 2016, 27, 1378-1381.	1.2	18
121	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews, 2016, 49, 65-76.	7.7	167
122	Reply to the letter to the editor â€ [*] Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?â€ [™] by Rodriguez-Wallberg et al Annals of Oncology, 2016, 27, 548-549.	1.2	8
123	Pediatric Outcome After Maternal Cancer Diagnosed During Pregnancy. Obstetrical and Gynecological Survey, 2016, 71, 144-146.	0.4	1
124	No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Journal of Clinical Oncology, 2016, 34, 2568-2574.	1.6	199
125	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. Journal of Clinical Oncology, 2016, 34, 501-508.	1.6	78
126	Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine, 2016, 14, 1.	5.5	521

#	Article	IF	CITATIONS
127	Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99.	2.2	142
128	Oncofertility. SpringerBriefs in Applied Sciences and Technology, 2016, , 97-104.	0.4	1
129	Fertility-Sparing Options in Young Women with Cervical Cancer. Current Treatment Options in Oncology, 2016, 17, 5.	3.0	19
130	Tongue cancer during pregnancy: Surgery and more, a multidisciplinary challenge. Critical Reviews in Oncology/Hematology, 2016, 98, 1-11.	4.4	11
131	Special issues in fertility preservation for gynecologic malignancies. Critical Reviews in Oncology/Hematology, 2016, 97, 206-219.	4.4	51
132	Managing Ovarian Tumors During Pregnancy. , 2016, , 149-158.		0
133	Abstract OT2-01-08: POSITIVE: A study evaluating pregnancy and disease outcome and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)., 2016,,.		1
134	Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. Ecancermedicalscience, 2015, 9, 584.	1.1	7
135	Chronic lymphocytic leukaemia during pregnancy: management and thoughts. Ecancermedicalscience, 2015, 9, 592.	1.1	3
136	Ovarian Protection during Adjuvant Chemotherapy. New England Journal of Medicine, 2015, 372, 2268-2270.	27.0	39
137	Attitudes on fertility issues in breast cancer patients: an Italian survey. Gynecological Endocrinology, 2015, 31, 458-464.	1.7	36
138	Breast Cancer During Pregnancy. , 2015, , 61-70.		1
139	Pregnancy After Breast Cancer. , 2015, , 71-82.		1
140	Contraception is as important as fertility preservation in young women with cancer. Lancet, The, 2015, 385, 508.	13.7	11
141	Exploring the safety of chemotherapy for treating breast cancer during pregnancy. Expert Opinion on Drug Safety, 2015, 14, 1395-1408.	2.4	18
142	Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. European Journal of Cancer, 2015, 51, 1490-1496.	2.8	64
143	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast, 2015, 24, 290-293.	2.2	27
144	Difficult choices for young patients with cancer: the supportive role of decisional counseling. Supportive Care in Cancer, 2015, 23, 3555-3562.	2,2	20

#	Article	IF	Citations
145	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. Breast, 2015, 24, 201-207.	2.2	97
146	RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Research, 2015, 17, 24.	5.0	149
147	After gestational chemotherapy, the kids are all right. Nature Reviews Clinical Oncology, 2015, 12, 254-255.	27.6	5
148	Targeted agents for cancer treatment during pregnancy. Cancer Treatment Reviews, 2015, 41, 301-309.	7.7	84
149	Discrepancies between ESMO and NCCN breast cancer guidelines: AnÂappraisal. Breast, 2015, 24, 513-523.	2.2	26
150	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. New England Journal of Medicine, 2015, 373, 1824-1834.	27.0	283
151	Oocyte cryopreservation beyond cancer: tools for ethical reflection. Journal of Assisted Reproduction and Genetics, 2015, 32, 1211-1220.	2.5	19
152	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Annals of Oncology, 2015, 26, 2408-2419.	1.2	178
153	Abstract P6-01-01: RANK/RANKL expression by immunohistochemistry (IHC) in young breast cancer (BC) patients and during pregnancy: Association with clinicopathologic features, gene expression profiles and patient outcome., 2015,,.		0
154	Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. Anticancer Research, 2015, 35, 575-9.	1.1	4
155	Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation. Human Reproduction Update, 2014, 20, 944-951.	10.8	21
156	Locoregional treatment of breast cancer during pregnancy. Gynecological Surgery, 2014, 11, 279-284.	0.9	48
157	Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. European Respiratory Review, 2014, 23, 231-238.	7.1	34
158	Treatment Options for Pregnant Women With Ovarian Tumors. International Journal of Gynecological Cancer, 2014, 24, 967-972.	2.5	18
159	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	2.2	135
160	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 2014, 40, 675-683.	7.7	169
161	Biology of breast cancer during pregnancy using genomic profiling. Endocrine-Related Cancer, 2014, 21, 545-554.	3.1	58
162	Strategies for fertility preservation in young early breast cancer patients. Breast, 2014, 23, 503-510.	2,2	42

#	Article	IF	CITATIONS
163	Fertility preservation in cancer patients: The global framework. Cancer Treatment Reviews, 2014, 40, 1019-1027.	7.7	70
164	Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: A case report. Breast, 2014, 23, 295-296.	2.2	4
165	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 382.	1.1	5
166	Highâ€dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Hematological Oncology, 2013, 31, 34-40.	1.7	20
167	Are monoclonal antibodies a safe treatment for cancer during pregnancy?. Immunotherapy, 2013, 5, 733-741.	2.0	33
168	Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast, 2013, 22, 657-660.	2.2	46
169	Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding?. Cancer Treatment Reviews, 2013, 39, 207-211.	7.7	54
170	Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi160-vi170.	1.2	594
171	Lung cancer in pregnancy: Report of nine cases from an international collaborative study. Lung Cancer, 2013, 82, 499-505.	2.0	107
172	Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study. Journal of Clinical Oncology, 2013, 31, 73-79.	1.6	215
173	Reply to Z. Blumenfeld et al. Journal of Clinical Oncology, 2013, 31, 3722-3723.	1.6	1
174	Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial. Journal of Clinical Oncology, 2013, 31, 903-909.	1.6	108
175	ecancermedicalscience. Ecancermedicalscience, 2012, 6, 240.	1.1	5
176	Fertility Preservation Methods in Breast Cancer. Breast Care, 2012, 7, 197-202.	1.4	10
177	Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-12.	1.3	18
178	"The only thing I know is that I know nothing― 5-fluorouracil in human milk. Annals of Oncology, 2012, 23, 543-544.	1.2	7
179	The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study. Acta OncolÅ ³ gica, 2012, 51, 653-661.	1.8	65
180	Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. International Immunology, 2012, 24, 583-591.	4.0	20

#	Article	IF	Citations
181	Antiblastic Treatment and Haematological Malignancies during Pregnancy: A Crucial Decision. International Journal of Immunopathology and Pharmacology, 2012, 25, 21-32.	2.1	0
182	Obstetrical, Fetal and Postnatal Effects of Gestational Antiblastic Chemotherapy: How to Counsel Cancer Patients. International Journal of Immunopathology and Pharmacology, 2012, 25, 33-46.	2.1	2
183	Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies. Cancer Treatment Reviews, 2012, 38, 834-842.	7.7	199
184	The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. European Journal of Cancer, 2012, 48, 3355-3377.	2.8	237
185	ecancermedicalscience. Ecancermedicalscience, 2011, 5, 204.	1.1	6
186	Rituximab in Hodgkin lymphoma: Is the target always a hit?. Cancer Treatment Reviews, 2011, 37, 385-390.	7.7	38
187	Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies. European Journal of Cancer, 2011, 47, 74-83.	2.8	227
188	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. Human Pathology, 2011, 42, 254-268.	2.0	17
189	Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more …. Breast, 2011, 20, 1-6.	2.2	57
190	Motherhood after breast cancer: searching for la dolce vita. Expert Review of Anticancer Therapy, 2011, 11, 287-298.	2.4	41
191	Fatherhood during imatinib. Acta Oncológica, 2011, 50, 734-735.	1.8	26
192	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). Journal of Thoracic Disease, 2011, 3, 57-64.	1.4	16
193	Managing cancer during pregnancy: what evidence do we have?. Polish Archives of Internal Medicine, 2011, 121, 29-34.	0.4	3
194	ecancermedicalscience. Ecancermedicalscience, 2010, 4, 184.	1.1	1
195	Sentinel lymph node biopsy in pregnant patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 78-83.	6.4	123
196	Breastfeeding in breast cancer survivors: Pattern, behaviour and effect on breast cancer outcome. Breast, 2010, 19, 527-531.	2.2	44
197	Treatment of Cancer During Pregnancy: The Need for Tailored Strategies. Journal of Clinical Oncology, 2010, 28, e302-e303.	1.6	13
198	Lung cancer in the pregnant woman: To treat or not to treat, that is the question. Lung Cancer, 2010, 67, 251-256.	2.0	56

#	Article	IF	CITATIONS
199	504 Safety of pregnancy in breast cancer survivors: a meta-analysis. European Journal of Cancer, Supplement, 2010, 8, 207.	2.2	3
200	Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treatment Reviews, 2010, 36, 101-109.	7.7	117
201	Breast cancer in pregnancy: Recommendations of an international consensus meeting. European Journal of Cancer, 2010, 46, 3158-3168.	2.8	238
202	Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Cancer Treatment Reviews, 2010, 36, 110-121.	7.7	141
203	Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Review of Clinical Immunology, 2010, 6, 821-826.	3.0	74
204	Management of Anaplastic Large-Cell Lymphoma During Pregnancy. Journal of Clinical Oncology, 2009, 27, e75-e77.	1.6	8
205	Rituximab in Lymphocyte-Predominant Hodgkin Disease. Oncology, 2009, 76, 26-29.	1.9	14
206	Safety of pregnancy following breast cancer diagnosis. Acta Oncológica, 2009, 48, 470-471.	1.8	3
207	The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology, 2009, 20, 1344-1351.	1.2	15
208	Communication skills and raising awareness in clinical practice: An Italian experience. Ecancermedicalscience, 2009, 3, 135.	1.1	1
209	Pregnancy in breast cancer survivors: A need for proper counseling. Breast, 2009, 18, 337-338.	2.2	13
210	Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Research and Treatment, 2009, 115, 591-594.	2.5	68
211	Breast-feeding after breast cancer: if you wish, madam. Breast Cancer Research and Treatment, 2009, 114, 7-12.	2.5	41
212	Breast cancer and pregnancy: how safe is trastuzumab?. Nature Reviews Clinical Oncology, 2009, 6, 367-370.	27.6	39
213	Is Electron Beam Intraoperative Radiotherapy (ELIOT) Safe in Pregnant Women with Early Breast Cancer? In Vivo Dosimetry to Assess Fetal Dose. Annals of Surgical Oncology, 2009, 16, 100-5.	1.5	27
214	GnRH analogue for chemotherapy-induced ovarian damage: too early to say?. Fertility and Sterility, 2009, 92, e33.	1.0	12
215	Have we reached a plateau in adjuvant breast cancer therapy?. Lancet, The, 2009, 374, 1421.	13.7	0
216	Carboplatin and Weekly Paclitaxel for the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) During Pregnancy. Journal of Thoracic Oncology, 2009, 4, 559-560.	1.1	20

#	Article	IF	Citations
217	Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. Journal of Clinical Oncology, 2009, 27, 8512-8512.	1.6	6
218	Rituximab Reduces Anti-UL94 and Anti-NAG-2 Antibodies Titer and Is Effective against Skin-Chronic Graft Versus Host Disease Resembling Scleroderma Blood, 2009, 114, 4654-4654.	1.4	4
219	Treatment of metastatic breast cancer during pregnancy: We need to talk!. Breast, 2008, 17, 426-428.	2.2	8
220	Extramedullary Myeloid Sarcoma of the Breast. Journal of Clinical Oncology, 2008, 26, 4041-4043.	1.6	13
221	Circulating Endothelial Cell Number and Viability Are Reduced by Exposure to High Altitude. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 53-58.	1.7	12
222	Anthracyclines for gestational breast cancer: course and outcome of pregnancy. Annals of Oncology, 2008, 19, 1511-1512.	1.2	22
223	Cancer and Pregnancy. Recent Results in Cancer Research, 2008, , .	1.8	9
224	Why Is the Topic of Cancer and Pregnancy So Important? Why and How to Read this Book. , 2008, 178, 1-2.		8
225	Subsequent Pregnancy After Breast Cancer. , 2008, 178, 57-67.		18
226	Primary Female Genital Lymphoma: Prognostic and Therapeutic Considerations. Blood, 2008, 112, 4941-4941.	1.4	0
227	lgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease. Blood, 2008, 112, 1169-1169.	1.4	О
228	Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano. Blood, 2008, 112, 5016-5016.	1.4	5
229	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Annals of Oncology, 2007, 18, 1177-1184.	1.2	8
230	Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin's Lymphoma (HL): A Single Centre Experience Blood, 2007, 110, 4463-4463.	1.4	0
231	Unmet needs of cancer survivors: supportive care's new challenge. Supportive Care in Cancer, 2006, 14, 397-399.	2.2	19
232	Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. Journal of Clinical Oncology, 2006, 24, 370-378.	1.6	67
233	Valganciclovir Is Safe and Effective as Pre-Emptive Treatment for CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2006, 108, 5300-5300.	1.4	1
234	Mediastinal-like growing teratoma syndrome. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 228-229.	0.8	4

#	Article	IF	Citations
235	Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Journal of Clinical Oncology, 2005, 23, 232-233.	1.6	5
236	Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. European Journal of Surgical Oncology, 2005, 31, 232-236.	1.0	62
237	Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation in Renal Cell Carcinoma: The EIO Experience Blood, 2005, 106, 5424-5424.	1.4	0
238	Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report Blood, 2005, 106, 5401-5401.	1.4	0
239	High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis Blood, 2005, 106, 5506-5506.	1.4	0
240	Graft-Versus-Lymphoma Effect in Hodgkin's Disease: A Possible Role in Maintaining a Disease Control Blood, 2005, 106, 5423-5423.	1.4	0
241	Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. Circulation, 2004, 109, 2749-2754.	1.6	797
242	ChlVPP/ABVVP, a first line â€~hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. British Journal of Haematology, 2004, 125, 584-589.	2.5	10
243	Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. European Journal of Cancer, 2004, 40, 563-570.	2.8	13
244	Autologous Peripheral Blood Stem Cell Transplantation for Myocardial Regeneration: A Novel Strategy for Cell Collection and Surgical Injection. Annals of Thoracic Surgery, 2004, 78, 1808-1812.	1.3	73
245	Chemotherapy during pregnancy: what is really safe?. Lancet Oncology, The, 2004, 5, 398.	10.7	32
246	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. Clinical Cancer Research, 2004, 10, 6039-6046.	7.0	18
247	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 2004, 103, 4416-4423.	1.4	531
248	Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab Blood, 2004, 104, 4629-4629.	1.4	0
249	ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2003, 44, 801-806.	1.3	10
250	Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients. Leukemia and Lymphoma, 2003, 44, 1919-1923.	1.3	13
251	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.	1.4	391
252	Short- and long-term safety of the 2 \tilde{A} — 106 CD34+ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support. Annals of Oncology, 2002, 13, 983-984.	1.2	2

#	Article	IF	CITATIONS
253	Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Annals of Oncology, 2001, 12, 987-990.	1.2	81
254	Title is missing!. Annals of Oncology, 2001, 12, 1333-1333.	1.2	0
255	Adverse effects associated with extracorporeal photochemotherapy. Transfusion, 2000, 40, 121-121.	1.6	17
256	REPLY TO GUNSILIUS ET AL. British Journal of Haematology, 2000, 108, 662-663.	2.5	0
257	Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplantation, 2000, 25, 173-177.	2.4	40
258	Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Annals of Oncology, 2000, 11, 977-984.	1.2	66
259	Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LYy355703. Obstetrics and Gynecology, 2000, 95, 1030.	2.4	1
260	ChlVPP/ABV-VP16 Hybrid Regimen for Advanced Hodgkin's Disease: a Study in 36 Patients. Leukemia and Lymphoma, 1999, 33, 313-319.	1.3	2
261	Angiogenic growth factors and endostatin in nonâ€Hodgkin's lymphoma. British Journal of Haematology, 1999, 106, 504-509.	2.5	151
262	Expression of CD3- $\hat{\mathbf{l}}$ ¶ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. British Journal of Cancer, 1999, 79, 1127-1132.	6.4	31
263	Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device. Bone Marrow Transplantation, 1999, 24, 89-93.	2.4	35
264	Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Annals of Oncology, 1998, 9, 913-916.	1.2	8
265	Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy Journal of Clinical Oncology, 1996, 14, 628-635.	1.6	30
266	Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstetrics and Gynecology, 1995, 86, 367-372.	2.4	97
267	Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Annals of Oncology, 1994, 5, 935-941.	1.2	48
268	Primary Ovarian Small Cell Carcinoma: Four More Cases. Gynecologic Oncology, 1993, 49, 95-99.	1.4	30
269	High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease — A 6-year update. Annals of Oncology, 1993, 4, 889-891.	1.2	61

Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7) Tj ETQq0 0 0 0 rgBT /Overlock 10 Tf 5 270

#	Article	IF	CITATIONS
271	Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). Stem Cells, 1993, 11, 72-75.	3.2	5
272	Anti-tumor and immunomodulatory activity of intraperitoneal IFN- \hat{l}^3 in ovarian carcinoma patients with minimal residual tumor after chemotherapy. International Journal of Cancer, 1992, 51, 42-46.	5.1	78
273	Killing of Tumor Cells with Pleiotropic Drug Resistance by OK432-Activated Effector Cells. Immunopharmacology and Immunotoxicology, 1989, 11, 257-268.	2.4	2
274	T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions. Cytotechnology, 1987, 1, 79-81.	1.6	0
275	Psychological Well-Being, Prenatal Attachment, and Quality of Early Mother-Infant Interaction: A Pilot Study With a Sample of Mothers With or Without Cancer History. Frontiers in Psychology, 0, 13,	2.1	1